2015
DOI: 10.1124/mol.115.100693
|View full text |Cite
|
Sign up to set email alerts
|

Molecular Interactions and Implications of Aldose Reductase Inhibition by PGA1 and Clinically Used Prostaglandins

Abstract: Aldose reductase (AKR1B1) is a critical drug target because of its involvement in diabetic complications, inflammation, and tumorigenesis. However, to date, development of clinically useful inhibitors has been largely unsuccessful. Cyclopentenone prostaglandins (cyPGs) are reactive lipid mediators that bind covalently to proteins and exert anti-inflammatory and antiproliferative effects in numerous settings. By pursuing targets for modification by cyPGs we have found that the cyPG PGA 1 binds to and inactivate… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

1
15
0

Year Published

2016
2016
2024
2024

Publication Types

Select...
8

Relationship

2
6

Authors

Journals

citations
Cited by 18 publications
(16 citation statements)
references
References 57 publications
1
15
0
Order By: Relevance
“… 24 More recently, other potential clinical uses of PGA 1 or its analogs have been explored, including the potential beneficial effects of A-type cyclopentenone prostaglandins in atherosclerosis 44 and its potential use in the inhibition of the aldo-keto reductase enzymes, which are involved in cancer resistance to chemical treatment and in the development of diabetic complications. 45 , 46 Here our data highlight the possibility that cyclopentenone prostaglandins, because of their specific cellular effects, can be useful in the design of new therapeutic drugs and these studies are under way.…”
Section: Discussionmentioning
confidence: 70%
“… 24 More recently, other potential clinical uses of PGA 1 or its analogs have been explored, including the potential beneficial effects of A-type cyclopentenone prostaglandins in atherosclerosis 44 and its potential use in the inhibition of the aldo-keto reductase enzymes, which are involved in cancer resistance to chemical treatment and in the development of diabetic complications. 45 , 46 Here our data highlight the possibility that cyclopentenone prostaglandins, because of their specific cellular effects, can be useful in the design of new therapeutic drugs and these studies are under way.…”
Section: Discussionmentioning
confidence: 70%
“…Increased aldose reductase activity is a well‐established pathogenic factor for several diseases, for which it is considered a crucial drug target (Díez‐Dacal et al., ). Accumulating evidence indicates that it plays a complex role in inflammation (Sánchez‐Gómez et al., ; Srivastava et al., ).…”
Section: Discussionmentioning
confidence: 99%
“…However, processing of high levels of reactive species could lead to generation of proinflammatory metabolites and/or depletion of antioxidant defenses, for which a positive inflammatory feedback may occur (Ramana et al., ). Remarkably, AKR1B1 itself is a target for covalent modification by electrophilic species, which can stimulate or inhibit its activity depending on the modifying moiety (Díez‐Dacal et al., ; Srivastava et al., ). Therefore, understanding the involvement of AKR1B1 in a particular pathology requires detailed consideration of the multiple factors involved.…”
Section: Discussionmentioning
confidence: 99%
“…MS approaches exist that allow detection of non-covalent drug protein complexes. In the case of the enzyme aldose reductase, a complex with non-electrophilic prostaglandins that is reversed under denaturing conditions has been observed by MALDI-TOF MS [52]. This type of interaction can affect the function and conformation of the proteins and/or shield specific sites for modification by other drugs or endogenous mediators.…”
Section: Non-covalent Drug-protein Interactionsmentioning
confidence: 99%